OBJECTIVE: Obesity is associated with increased morbidity and mortality from atherosclerotic disease. Nontraditional cardiovascular risk factors such as C-reactive protein (CRP) and interleukin-6 (IL-6) are elevated in obese subjects and weight loss is associated with an attenuation of these risk factors. Matrix metalloproteinase-9 (MMP-9) has been linked to plaque rupture, and is, thus, a candidate marker of future myocardial events. The aim of this study was to determine the influence of weight loss on MMP-9 plasma concentrations. METHODS AND RESULTS: CRP, IL-6 and MMP-9 were analyzed from samples of 45 morbidly obese, middle-aged women before gastric banding and 1 y postsurgical treatment in this prospective study. The body mass index (BMI) of subjects decreased from 42.574.9 to 32.375.3 kg/m 2 1 y after gastric banding. In parallel, both MMP-9 and CRP were reduced by 23 and 41%, respectively. A positive relationship was found between BMI and MMP-9 (r ¼ 0.312, Po0.05), and between CRP and IL-6 (r ¼ 0.508, Po0.05), whereas no correlation was found between CRP and MMP-9. CONCLUSIONS: We conclude that weight loss is associated with a pronounced decrease in the nontraditional cardiovascular risk markers MMP-9 and CRP, which could indicate future beneficial effects of weight loss on the cardiovascular risk in weight loosing subjects.
Introduction
Obesity is associated with a variety of metabolic and hormonal dysfunctions such as the development of insulin resistance and dyslipidemia, leading to increased morbidity and mortality in these subjects. 1, 2 Several studies indicate a close relationship between atherosclerotic disease and inflammation. Inflammation seems to play a key role in the initiation, progression and rupture of the atherosclerotic plaque.
3 C-reactive protein (CRP), the major acute phase protein, is a sensitive marker for systemic inflammation and obesity is accompanied by low-grade inflammation. 4 The main stimulators of CRP production are interleukin-6 (IL-6) and TNF-a; both cytokines are expressed and secreted by adipocytes. Matrix metalloproteinase-9 (MMP-9) is an additional biological marker of the inflammatory process and plaque instability. 5 The expression of MMP-9 is induced in atherosclerotic plaques prone to rupture and, as a consequence, also the plasma levels of MMP-9 are elevated in patients with atherosclerotic disease. 6 Bariatric surgery is an efficient method to reduce body weight. Long-term results from the Swedish Obese Subjects Study (SOS) revealed a substantial reduction of several cardiovascular risk factors in surgically treated obese patients. 7 Several other beneficial metabolic effects such as the reversibility of the atherogenic lipoprotein profile by lowering triglycerides, increasing HDL cholesterol and the LDL particle diameter have been described. 8 Hormones, involved in the pathogenesis of adiposity, such as leptin and ghrelin, are also regulated by weight loss. 9, 10 Furthermore, weight reduction is connected to an improvement of the insulin resistance syndrome and a pronounced reduction of CRP. [11] [12] [13] To investigate the reversibility of the association between the nontraditional risk markers CRP and MMP-9 and obesity, we performed a prospective study in morbidly obese, middle-aged women undergoing weight loss by surgical intervention.
Subjects and methods

Subjects
In all, 45 morbidly obese women defined by a body mass index (BMI) of more than 40 kg/m 2 participated in this prospective study. Exclusion criteria were secondary causes of adiposity, diabetes mellitus, pregnancy, intake of lipid lowering drugs or other medically significant illness. Examinations of the study subjects were undertaken within 2 months prior to Swedish Adjustable Gastric Banding (SAGB) and 1 y post-SAGB. Informed consent was obtained from all subjects, and the procedures were performed in accordance with institutional guidelines at the Clinical Department of Internal Medicine of the Medical University Innsbruck.
Surgical procedure
The surgical procedure were performed as described by Forsell 14 at the Department of Surgery, University of Innsbruck. The Swedish Adjustable Gastric Band was used in all of the study patients (SAGB Obtech Medical AG, Zug, Switzerland).
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Analyses Blood was drawn after an overnight fast from an antecubital vein into EDTA tubes (1.6 mg/ml). Plasma was separated from erythrocytes by centrifugation at 3000 r.p.m. for 10 min at 41C immediately after collection. Plasma samples were stored frozen at À801C until assayed. CRP concentration was measured using the CRP (Latex) ultrasensitive assay (Roche Diagnostic Systems, Basel, Switzerland). IL-6 and MMP-9 were determined using the commercially available IL-6-and MMP-9-ELISAs, respectively (R & D, Vienna, Austria). The intra-assay CV for the IL-6 assay is between 6.9 and 7.8% as provided by the supplier. The mean minimum detectable dose is 0.039 pg/ml. The intra-assay CV for the MMP-9 assay is between 1.9 and 2.9%. The mean minimum detectable dose is 0.156 ng/ml.
The homeostasis model assessment (HOMA) index for beta-cell function and for insulin resistance were calculated as described in detail elsewhere. [16] [17] [18] Statistical analysis Descriptive data are expressed as mean value7s.d. The data from the pre-and postgastric banding group were compared using a paired-samples t-test. Statistical significance was inferred at a two-tailed P-value of less than 0.05. Linear association between the D values of variables under investigation were calculated using the method of Pearson's correlation coefficient. Statistical analyses were calculated using SPSS release 8.0 for Windows (SPSS, Chicago, IL, USA).
Results
Anthropomorphic measures of the study subjects are shown in Table 1 . The mean age at baseline was 39.7 y. In pregastric banding subjects, the body weight was 116.6714. The CRP concentration was 0.8670.91 mg/dl before gastric banding and fell to 0.5170.62 mg/dl (P ¼ 0.004) after weight loss. The IL-6 concentration was 5.074.2 pg/ml in pregastric banding subjects. In these subjects, the IL-6 concentration decreased to 3.974.3 pg/ml after the gastric banding procedure (P ¼ 0.125). WBC levels were 758772704 in pregastric banding women and 657071905 cells/mm 3 postgastric banding (P ¼ 0.05). The baseline MMP-9 concentration was 380.27204.8 ng/ml. At 1 y after the surgical procedure, MMP-9 concentration decreased significantly by 90 to 291.17141.3 ng/ml (P ¼ 0.004).
To estimate the influence of weight loss on the reduction of MMP-9 levels, we performed a correlation analysis between the D values of BMI, MMP-9, CRP and IL-6, respectively (Table 2 ). A positive relationship was found between BMI and MMP-9 reduction (r ¼ 0.312, P ¼ 0.037).
Discussion
Obesity is associated with a variety of metabolic dysfunctions such as insulin resistance and dyslipidemia, leading to increased morbidity and mortality from atherosclerotic disease. 2 Bariatric surgery is an efficient method to reduce body weight in morbidly obese patients and thereby improve metabolic disorders and reduce obesity-associated diseases.
8,11-13 In this prospective study, we report that weight loss induced by gastric banding leads to significant reductions of MMP-9 and CRP plasma concentrations. IL-6 concentration declined after a pronounced weight loss of 24% of the initial weight. Furthermore, a positive relationship between weight loss and MMP-9 reduction could be demonstrated.
Obesity is associated with subclinical inflammation as indicated by elevated CRP levels and several prospective studies proved CRP as a risk factor for cardiovascular disease. 19 The subclinical inflammation associated with obesity is reversible by weight loss, which also leads to a consistent reduction of CRP concentration. 11, 12, 20 MMP-9 secretion by macrophages and other inflammatory cells accelerates atherosclerotic progression and destabilizes vulnerable plaque in animal models. MMP-9 has been demonstrated to be highly expressed in the vulnerable regions of atherosclerotic plaques, 21, 22 and the abundance of MMP-9 has been related to ruptured carotid plaques. 6 Recently, MMP-9 has been evaluated as a risk factor for cardiovascular morbidity and mortality, and thereby it has been related to future cardiovascular events. 23 Furthermore, MMP-9 levels are increased in patients with premature atherosclerosis. 24 Thus, a reduction in MMP-9 levels might be beneficial and associated with a diminution in overall cardiovascular risk. Furthermore, IL-8 has been demonstrated to be a potential proatherogenic factor. This might be due to the diminuting effect of IL-8 on tissue inhibitors of metalloproteinases (TIMP-1). The imbalance in the inhibitory effect of TIMP-1 on MMP activities could be responsible for the proatherogenic effect of IL-8.
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MMP-9 reducing effects were recently found in type 2 diabetic patients treated with the insulin sensitizer rosiglitazone. 26, 27 In this study, type 2 diabetic patients with coronary artery disease had increased levels of circulating MMP-9. After a treatment period of 2 weeks with the thiazolidinedione rosiglitazone, a reduction of circulating MMP-9 levels by 19.6% was found in these patients ( Figure 1 ). It is well documented that weight reduction leads to an improvement of insulin resistance syndrome. In the present study, HOMA indices calculated in a subpopulation of 19 individuals show a significant decrease after weight loss. According to the results of Haffner et al, we speculate on a possible effect of increasing insulin sensitivity on MMP-9 reduction in weight loosing subjects. Owing to the limited study population, no significant relationship was found between MMP-9 levels and the indices for insulin sensitivity, although a positive correlation was observed.
In conclusion, weight loss is associated with a pronounced decrease in the nontraditional cardiovascular risk markers MMP-9 and CRP, which could indicate future beneficial effects of weight loss on the cardiovascular risk in obese women. Weight loss and MMP-9 M Laimer et al
